Medical device innovators often focus on surgical procedures, device functionality, and preclinical endpoints when preparing for GLP studies. Histopathology requirements frequently get treated as presumptive afterthoughts, until tissue processing reveals that your study wasn't ready to begin.
All too often, startups and early-stage medical device companies initiate GLP preclinical studies without understanding how histology requirements impact every upstream decision. Device design. Sample size. Budget. Timeline. Protocol structure. When histology preparedness is ignored, the consequences are expensive: protocol deviations, inadequate data, and repeat studies that delay market entry by months.
You're not ready if: Your device has never been processed through histology methods, or you're relying on a "similar enough" predicate without actual validation.
Why this matters: Different device materials, hardnesses, and compositions require fundamentally different histology processing. A device that requires plastic embedding instead of paraffin adds 8 weeks to your timeline and limits the number of sections you can obtain. Some materials degrade in standard formalin fixatives. Others can't be sectioned without specialized equipment.
One medical device degraded completely in formalin (the most common tissue preservation method) because no one had tested fixation compatibility. By the time samples reached histology, the device had disintegrated, rendering the entire preclinical study unreliable.
What to do: Run pilot histology on your final device iteration. Test compatibility with fixation protocols, processing methods, and sectioning requirements. Confirm that your device can be processed using your planned histology approach before committing to GLP. Non-GLP (frequently deemed or dubbed “pilot”) studies are the time for discovery, methods testing, and adjusting the device or tissue collection while GLP studies are for repeating an experiment, in a controlled environment and collecting data for FDA submission.
For example, in your non-GLP study, consider sending the test article through fixative, embedding, and sectioning procedures. If this is a novel material, consider sending just the material for methods testing prior to histologic processing of study tissues. For GLP studies, follow Title 21 CFR 58.120 which requires the Test and Control Article to be listed, as well as methods described, and the type of analysis and measurements needed.
You're not ready if: You haven't finalized and locked out all potential changes to your test articles assigned to the GLP preclinical study.
Why this matters: Any change to device composition, hardness, chemical formulation, or structure can invalidate your histology methods and runs afoul of regulatory requirements for GLP studies per 21CFR58 of the United States Code. If you modify the device mid-study, you may need to section through different regions of interest (such as bone instead of soft tissue), switch from paraffin to plastic embedding, or abandon special stains that no longer work with the new material.
These aren't minor adjustments. They're study-altering changes that trigger protocol deviations and compromise data integrity.
What to do: Achieve complete design lock before GLP initiation. This includes material characterization, manufacturing processes, and all specifications that could impact how the device behaves in tissue.
You're not ready if: You can't specify how many histology sections you need, what measurements are required, or whether longitudinal versus cross-sectional cuts are necessary.
Why this matters: Histology isn't infinitely flexible. A 5mm piece of tissue embedded in plastic might yield only two usable slides before the tissue is exhausted. If you need four sections and only discover this during processing, there's no going back. The tissue is gone.
Similarly, if you realize mid-study that you need longitudinal sections when the protocol specifies cross-sections, the tissue has already been trimmed. You can't recover what's been cut.
What to do: Determine your exact histology needs during protocol development. Know how many sections you can physically obtain from your regions of interest. Understand whether paraffin or plastic processing gives you the sectioning flexibility your study requires. Build these specifications into your protocol before study initiation.
You're not ready if: You're trying to use paraffin processing when your device requires plastic embedding, or you lack funding for the histology methods your study actually needs.
Why this matters: Paraffin and plastic embedding aren't interchangeable. Hard devices, metal implants, and materials that can't be cut with standard microtomes require plastic processing. Plastic embedding costs more and takes longer (8 weeks minimum), but compromising on this requirement produces unusable slides.
Running out of money mid-study and defaulting to inadequate processing methods generates poor-quality histology that regulatory reviewers will question. You'll get slides, but not the publication-quality images and reliable data your submission requires.
What to do: Budget for the histology techniques your device realistically requires by consulting with the histopathology team to obtain detailed histology cost estimates during protocol development. Understand that plastic embedding, special stains, and immunohistochemistry each have specific cost and timeline implications.
You're not ready if: Your GLP protocol lacks specific histology methods, sample requirements, processing approaches, or contingency language for pathologist-directed additional sections.
Why this matters: Protocols that treat histology as a generic "tissue evaluation" step set you up for deviations, most requiring formal documentation within the body of the report. Your protocol should specify whether you're using paraffin or plastic processing, what stains are required, how many sections per region of interest, and what measurements the pathologist will perform. Finalizing a study protocol prior to pathology consultation may result in planned deviations or protocol amendments which require authorization and review by the Quality Assurance Unit. Waiting for approval will further delay your study deadline.
Without this specificity, you can't accurately estimate costs, timelines, or data outputs. More critically, you can't determine whether the histology plan is even feasible for your device and study design.
What to do: Work with your histopathology team during preclinical protocol development, especially GLP, to specify exact methods, processing requirements, and sample handling procedures. Include language allowing additional sections or special stains at pathologist discretion. This prevents deviations when unexpected findings require verification.
You're not ready if: You plan to engage histopathology expertise only after your GLP preclinical study has begun, treating pathologists as service providers rather than study design partners.
Why this matters: Board-certified veterinary pathologists who specialize in medical device work understand what regulators need, what processing methods work for different device types, and what can go wrong when histology isn't considered upfront. They can identify fatal flaws in your study design before you've spent hundreds of thousands of dollars.
What to do: Engage your pathologist during protocol development, not after tissue collection. Review device compatibility with histology methods. Validate that your sample sizes provide adequate statistical power accounting for tissue that may be diverted for other analyses. Confirm that your timeline allows for proper histology processing without rushing.
Here's what many innovators don't realize: It doesn't matter what you've promised investors, what your CEO announced, or what timeline you've committed to. Histopathology results arrive when physics allows, not when corporate goals demand.
Plastic embedding takes 8 weeks minimum. Tissue processing, quality review, and pathologist interpretation follow fixed timelines. Promising faster delivery doesn't make it happen. It just creates panic reading, poor data quality, and regulatory questions.
As detailed in our companion article on how histopathology exposes GLP failures, timeline pressure is one of the most common (and most avoidable) failure modes in medical device testing.
At Veranex, our histopathology capabilities in Paris and Worcester are seamlessly integrated with our world-renowned preclinical research facilities in Atlanta and Paris. Our board-certified veterinary pathologists engage during protocol development (not just slide reading) to ensure your study design accounts for histology requirements from the start.
We've supported over 200 regulatory submissions with histopathology that accelerates approval rather than triggering questions. Our expertise spans cardiovascular, neurology, orthopedics, ophthalmology, and regenerative medicine devices, giving us deep knowledge of how different device types behave in tissue.
We don't just tell you what went wrong after the fact. We help you design medical device studies that address histology requirements upfront, validating methods through pilot work and protecting your samples throughout GLP execution.
If you're evaluating your readiness for GLP preclinical work or need a partner who understands medical device histology from protocol to regulatory submission, contact our team today. Let's ensure you're truly ready before you invest.
Table: GLP Histopathology Best Practices
|
Practice |
21CFR58 Clause |
Rationale |
|
Full test article characterization |
58.105, 58.120 |
Regulatory requirement; prevents invalid data from uncharacterized changes |
|
Specific protocol for histology |
58.120, 58.130 |
Ensures all planned and contingency methods are pre-approved and deviations are minimized |
|
Validated SOPs |
58.81 |
Written procedures for all critical steps, enabling reproducibility and compliance checks |
|
Pilot histology work |
Best Practice |
Detects device/material incompatibilities before formal study, limits costly repeats |
|
Budgeting for method requirements |
Planning Step |
Prevents mid-study downgrades (e.g., switching from plastic to paraffin, resulting in unusable slides) |
|
Consultation with pathologist & QA |
58.33, 58.35 |
Prevents omission of endpoints, sample errors, and ensures correct handling/interpretation |
About the author: Kirsten Landsgaard is a board-certified anatomic pathologist with the American College of Veterinary Pathologists (ACVP). Her experience spans multiple geographic areas. Her expertise includes study design, necropsy, GLP compliant pathology reporting and evaluation of tissues and devices including post-market surveillance. She is proficient with Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), and micro-CT. Her experience further includes vascular occlusion devices, vascular grafts, ventricular assist devices, intra-aortic balloon pumps, orthopedic devices, subcutaneous sensors, and reproductive devices.